Myasthenia gravis


00:00 / 00:00



Myasthenia gravis

Immune system

General infections


Neonatal sepsis


Hypersensitivity reactions

Type I hypersensitivity

Food allergy



Type II hypersensitivity

Immune thrombocytopenic purpura

Autoimmune hemolytic anemia

Hemolytic disease of the newborn

Goodpasture syndrome

Rheumatic heart disease

Myasthenia gravis

Graves disease

Pemphigus vulgaris

Type III hypersensitivity

Serum sickness

Systemic lupus erythematosus

Poststreptococcal glomerulonephritis

Type IV hypersensitivity

Graft-versus-host disease

Contact dermatitis


Transplant rejection

Graft-versus-host disease

Cytomegalovirus infection after transplant (NORD)

Post-transplant lymphoproliferative disorders (NORD)


X-linked agammaglobulinemia

Selective immunoglobulin A deficiency

Common variable immunodeficiency

IgG subclass deficiency

Hyperimmunoglobulin E syndrome

Isolated primary immunoglobulin M deficiency

Thymic aplasia

DiGeorge syndrome

Severe combined immunodeficiency

Adenosine deaminase deficiency


Hyper IgM syndrome

Wiskott-Aldrich syndrome

Leukocyte adhesion deficiency

Chediak-Higashi syndrome

Chronic granulomatous disease

Complement deficiency

Hereditary angioedema


Immune system organ disorders


Ruptured spleen

Immune system pathology review

Blood transfusion reactions and transplant rejection: Pathology review

Immunodeficiencies: T-cell and B-cell disorders: Pathology review

Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review

Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review


Myasthenia gravis


0 / 12 complete

USMLE® Step 1 questions

0 / 5 complete

High Yield Notes

5 pages


Myasthenia gravis

of complete


USMLE® Step 1 style questions USMLE

of complete

A 38-year-old man comes to his primary care physician for evaluation of intermittent muscle weakness that began around three months ago. He reports having episodes of “seeing-double” and having difficulty chewing that occur in the evening and resolve the next morning. Past medical history is notable for asthma, for which he intermittently uses an albuterol inhaler. His temperature is 37.6°C (99.7°F), pulse is 65/min and blood pressure is 122/71 mmHg. During the physical examination, the patient is asked to look upwards toward the ceiling for 60 seconds. This maneuver elicits bilateral diplopia. The remainder of the examination is noncontributory. Workup is sent to confirm the diagnosis, and the patient is started on the first-line medication for his condition. Which of the following is a likely side-effect from overdose of this medication?

External References

First Aid









myasthenia gravis p. 484

Edrophonium p. 241, 571

myasthenia gravis diagnosis p. 483

Myasthenia gravis p. 484

autoantibody p. 113

diagnosis of p. 241

neostigmine for p. 241

as paraneoplastic syndrome p. 221

pyridostigmine for p. 241

restrictive lung disease p. 700

thymoma association p. 96

type II hypersensitivity p. 110

Ptosis (eyelids)

myasthenia gravis p. 483

Pyridostigmine p. 241

myasthenia gravis treatment p. 484

Thymic hyperplasia

myasthenia gravis association p. 483


myasthenia gravis and p. 221, 483


Content Reviewers

Rishi Desai, MD, MPH


Tanner Marshall, MS

Myasthenia gravis, is a Latin expression that literally means “grave muscle weakness,” which perfectly describes the weakness that happens when this autoimmune disease affects the skeletal muscles.

People with myasthenia gravis might wake up feeling fine, but get progressively weaker as the day goes on and by the end of the day they might feel very weak, sometimes even getting weaker with repetitive movements like chopping vegetables.

Myasthenia gravis can affect the extraocular muscles, which control movement of the eye as well as the eyelids, so individuals might have diplopia or double vision, as well as ptosis, or drooping eyelids.

Myasthenia gravis preferentially affects young women in their 20s and 30s and older men in their 60s and 70s, but the cause of this odd “bimodal” distribution of age-of-onset isn’t quite clear.

To better understand myasthenia gravis, let’s review normal muscle contraction but at the cellular level.

First you’ve got your motor neurons that release the neurotransmitter acetylcholine at the neuromuscular junction, which then binds to nicotinic acetylcholine receptors on muscle cell membranes.

Binding of acetylcholine to its receptor activates a chain reaction in the muscle cell that ultimately results in muscle contraction.

But what happens in myasthenia gravis though? Well remember that it’s an autoimmune disease, specifically one that’s categorized as a type II hypersensitivity which causes cytotoxic injury meaning that it results in the lysis or death of host cells, which is mediated by autoantibodies, which are antibodies that are specific for our own cells or proteins.

Alright, so in this case, the patient’s B cells inappropriately make antibodies that bind to nicotinic acetylcholine receptors on the muscle cells.

Once acetylcholine receptors are bound by the antibody, they are unable to bind to acetylcholine, and therefore don’t respond to the “contract” signal from the central nervous system.


Myasthenia gravis is an autoimmune disease, specifically a type II hypersensitivity disorder, which is characterized by autoantibodies against nicotinic acetylcholine receptors on the surface of muscle cells.

The antibodies block the receptors which means the signal to contract isn't received. Those antibodies also activate the complement pathway which leads to muscle cell destruction.

Symptoms can range from mild to severe and may include drooping eyelids, difficulty speaking or swallowing, and muscle weakness in the arms and legs. Treatment involves immunosuppressive drugs like prednisolone, and acetylcholinesterase inhibitors like neostigmine. The purpose is to reduce the immune system's attack on the muscle and to increase muscle strength.


  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine" McGraw Hill Education/ Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes" Cochrane Database of Systematic Reviews (2014)
  6. "The myasthenic patient in crisis: an update of the management in Neurointensive Care Unit" Arquivos de Neuro-Psiquiatria (2013)

Copyright © 2023 Elsevier, except certain content provided by third parties

Cookies are used by this site.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.